Compare Cytokinetics Inc (CYTK) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Genuine Parts Company — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Genuine Parts Company trades at $127.56 (market cap $17.67B). The key difference: Genuine Parts Company is far larger — about 2× Cytokinetics Inc's market cap, and Genuine Parts Company pays a 3.32% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Genuine Parts Company for 75 Days on average.
| CYTK | GPC | |
|---|---|---|
Market Cap | $8.62B | $17.67B |
Volume | 2,594,626 | 1,079,458 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $149.26 |
52-Week Low | $54.76 | $92.47 |
Typical Hold Time | 19 Days | 75 Days |
Enterprise Value | $8.72B | $23.76B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
GPC trades at $125.41, down 1.55% today, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a $145.75 price target with 43% buy ratings. Key developments include the planned spinoff of its industrial unit, Motion, in Q1 2027.
The outlook is cautious due to weak profitability and high P/E, but the spinoff could unlock value. Risks include execution challenges and economic sensitivity. Upside hinges on margin recovery and successful separation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
